A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2012
At a glance
- Drugs CX 157 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 13 Aug 2010 This trial will be supported by the proceeds of a recently completed $13 million Series C financing, according to a CeNeRx BioPharma media release.
- 05 Jul 2010 Status changed from recruiting to completed as results have been reported.
- 10 Jun 2010 Results were presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History